Skip to content

Impact of Flumazenil on the Emergence Delirium

The Impact of Administration of Flumazenil on the Emergence Delirium in Patients Anesthetized With Remimazolam: a Prospective Randomized Single-blind Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05681377
Enrollment
68
Registered
2023-01-12
Start date
2023-03-05
Completion date
2023-08-11
Last updated
2023-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, General

Keywords

Remimazolam, Flumazenil, Emergence delirium, Delirium

Brief summary

Flumazenil rapidly antagonizes benzodiazepines (BZDs); it may induce agitation, seizure, or delirium, especially when applied to patients who have taken BZDs for a long time. On the contrary, it may help patients regain consciousness in a stable and calm state by appropriately reversing the central nervous system depressant effects of BZDs. In this study, we aim to investigate the impact of flumazenil on the emergence delirium in patients anesthetized with remimazolam, the short-acting BZD drug.

Interventions

DRUGFlumazenil

After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.

Sponsors

Korea University Guro Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 19 years or older undergoing surgery under general anesthesia

Exclusion criteria

* Peripheral nerve block or Neuraxial block * Uncontrolled hypertension (HTN) (systolic blood pressure (SBP) ≥180 mmHg) * Uncontrolled diabetes mellitus (DM) (HbA1c ≥9.0%) * Hepatic dysfunction (Total bilirubin ≥3.0 mg/mL or Liver enzyme ≥Upper normal limit x 2.5) * Renal dysfunction (Estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73m2 or Dialysis) * Moderate or severe chronic obstructive pulmonary disease or Respiratory failure * Emergency * Hepatectomy or Liver transplantation * Intraoperative cardiopulmonary bypass (CPB) or extracorporeal membrane oxygenation (ECMO) use * Head trauma, Increased intracranial pressure, Craniotomy * Chronic use of benzodiazepines (BZDs) * Anxiety, Alcohol/Drug dependence, Addiction to tricyclic antidepressants (TCAs) * Allergic reaction to BZDs, flumazenil, or other drugs used in general anesthesia * Severe allergy or Anaphylaxis history * Lactose-related genetic disorders * Myasthenia gravis or Myasthenia gravis syndrome * Myocardial infarction or Cerebrovascular events within 6 months * Symptomatic coronary artery disease * Organic brain disease * Cognitive impairment (Inability to understand informed consent)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of emergence deliriumFrom emergence to postanesthesia care unit (PACU) discharge (Immediately after extubation, 15 min after PACU admission, PACU discharge) [within 2 hrs after surgery]Richmond Agitation & Sedation Scale (RASS) ≥1 is considered emergence delirium.

Secondary

MeasureTime frameDescription
Severity of PODFrom PACU to postoperative day 5CAM-severity (CAM-S) is utilized to determine the severity of POD if it occurs.
Duration of PODFrom PACU to postoperative day 53D-CAM is utilized to check the duration of POD.
Level of consciousnessFrom emergence to PACU discharge (Immediately after extubation, 15 min after PACU admission, PACU discharge) [within 2 hrs after surgeryRichmond Agitation & Sedation Scale (RASS) is used to evaluate the patients level of consciousness.
Incidence of resedationFrom emergence to PACU discharge (Immediately after extubation, 15 min after PACU admission, PACU discharge) [within 2 hrs after surgeryRichmond Agitation & Sedation Scale (RASS) ≤-2 is diagnosed as resedation.
Time to eye-openingAfter remimazolam cessation to eye-opening [within 30 min after remimazolam cessation]Time taken for patients to open their eyes when their name is gently called after discontinuation of remimazolam.
Incidence of postoperative delirium (POD)From PACU to postoperative day 5(until the discharge date if discharged before 5 days after surgery) [2 times a day in the morning/afternoon]3-Minute Diagnostic Assessment for Delirium using the Confusion Assessment Method (3D-CAM) is used for the evaluation of POD.
Preoperative anxiety1 day before surgeryAmsterdam Preoperative Anxiety and Information Scale (APAIS) is used to evaluate the patient's anxiety before surgery
Postoperative nausea/vomiting (PONV)From immediately after extubation to PACU discharge [within 2 hours after surgery]Confirm PONV through patient's symptoms and signs.
Postoperative painFrom PACU admission to postoperative day 5Numeric rating scale (NRS) or Visual analogue scale (VAS) is used to determine the patient's pain severity (\*NRS and VAS are measured on a 0-10 scale, and the higher the score, the more severe the patient's pain)
Postoperative hospital length of stayFrom the day of surgery to the day of hospital discharge [within 1 month]Calculate the days from the date of surgery to the date of hospital discharge.
Time to extubationAfter remimazolam cessation to extubation [within 30 min after remimazolam cessation]Time taken for patients to maintain spontaneous breathing and be extubated after remimazolam discontinuation.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026